A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis

2023-509357-31-00 Protocol BP42230 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 1 Jun 2021 · Status Ongoing, recruiting · 7 EU/EEA countries · 18 sites · Protocol BP42230

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 75
Countries 7
Sites 18

Multiple Sclerosis (MS)

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
1 Jun 2021 → ongoing
Decision date (initial)
2024-03-28
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-509357-31-00
EudraCT number
2020-004122-33

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Multiple Sclerosis (MS)

VersionLevelCodeTermSystem organ class
20.1 PT 10028245 Multiple sclerosis 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

7 EU/EEA countries · 18 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 9 2
Germany Ongoing, recruiting 12 5
Italy Ongoing, recruiting 3 2
Poland Ongoing, recruiting 10 3
Portugal Ongoing, recruiting 6 3
Romania Ongoing, recruiting 13 2
Spain Ongoing, recruiting 2 1
Rest of world
Canada, Moldova, Republic of, Israel, Russian Federation, United States, Serbia
20

Investigational sites

Belgium

2 sites · Ongoing, recruiting
Cliniques Universitaires Saint-Luc
Neurology, Hippokrateslaan 10, Batiment 54, Sint-Lambrechts-Woluwe
Universitair Ziekenhuis Gent
Neurology, Corneel Heymanslaan 10, 9000, Gent

Germany

5 sites · Ongoing, recruiting
Universitaetsklinikum Ulm AöR
Dept. of Neurology, Oberer Eselsberg 45, Eselsberg, Ulm
Klinikum rechts der Isar der TU Muenchen AöR
Neurologische Klinik und Poliklinik im Neuro-Kopf-Zentrum, Ismaninger Strasse 22, Au-Haidhausen, Munich
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
MS Center Dresden, Fetscherstrasse 74, Johannstadt-Nord, Dresden
Universitaetsklinikum Muenster AöR
Klinik u. Poliklinik f. Neurologie, Albert-Schweitzer-Campus 1, Sentrup, Muenster
Universitaetsklinikum Tuebingen AöR
Dept. of Neurology, Hoppe-Seyler-Strasse 3, Nordstadt, Tuebingen

Italy

2 sites · Ongoing, recruiting
Ospedale San Raffaele S.r.l.
Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla, Via Olgettina 60, 20132, Milan
IRCCS Foundation Istituto Neurologico Carlo Besta
U.O.C. Neurologia IV - Neuroimmunologia e Malattie Neuromuscolari, Via Giovanni Celoria 11, 20133, Milan

Poland

3 sites · Ongoing, recruiting
Samodzielny Publiczny Szpital Kliniczny Nr 1 Im.Prof.Stanislawa Szyszko Slaskiego Uniwersytetu Medycznego W Katowicach
Oddział Neurologiczny, Ul. 3 Maja 13/15, 41-800, Zabrze
Euromedis Sp. z o.o.
Centrum Medyczne EUROMEDIS, Ul. Powstancow Wielkopolskich 33 A, 70-111, Szczecin
Med Polonia Sp. z o.o.
NA, Obornicka 262, 60-693, Poznan

Portugal

3 sites · Ongoing, recruiting
Unidade Local De Saude De Entre O Douro E Vouga E.P.E.
Serviço de Neurologia, Rua Doutor Candido Pinho, 4520-211, Santa Maria Da Feira
CCAB Centro Clinico Academico Braga Associacao
Neurologia, Lugar De Sete Fontes S Victor, 4710-243, Braga
Unidade Local De Saude De Sao Jose E.P.E.
Centro de Responsabilidade Integrada de Esclerose Múltipla, Rua Jose Antonio Serrano, 1150-199, Lisbon

Romania

2 sites · Ongoing, recruiting
Spitalul Clinic Judetean De Urgenta Cluj
Neurology, Strada Clinicilor 3-5, 400006, Cluj-Napoca
Arensia Clinics S.R.L.
Neurology, Intrarea Tudor Stefan 38-40, 011658, Bucharest

Spain

1 site · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Neurology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2021-06-01 2022-06-08
Germany 2021-09-30 2022-07-20
Italy 2021-10-14 2024-01-22
Poland 2021-07-14 2021-07-15
Portugal 2022-09-12 2022-12-14
Romania 2023-05-12 2023-06-08
Spain 2025-03-14 2025-03-26

Application history

10 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-22 Germany Acceptable
2024-03-14
2024-03-15
2 SUBSTANTIAL MODIFICATION SM-1 2024-05-17 Germany Acceptable with conditions
2024-08-26
2024-08-26
3 SUBSTANTIAL MODIFICATION SM-2 2024-09-16 Germany Acceptable
2024-11-18
2024-11-20
4 SUBSEQUENT ADDITION OF MSC APP-4 2024-12-03 Acceptable
2024-11-18
2025-02-24
5 NON SUBSTANTIAL MODIFICATION NSM-1 2025-05-14 Acceptable
2024-11-18
2025-05-14
6 NON SUBSTANTIAL MODIFICATION NSM-2 2025-07-07 Germany Acceptable
2024-11-18
2025-07-07
7 NON SUBSTANTIAL MODIFICATION NSM-3 2025-08-18 Germany Acceptable
2024-11-18
2025-08-18
8 SUBSTANTIAL MODIFICATION SM-3 2025-09-18 Germany Acceptable
2026-01-05
2026-01-07
9 NON SUBSTANTIAL MODIFICATION NSM-4 2026-03-12 Germany Acceptable
2026-01-05
2026-03-12
10 SUBSTANTIAL MODIFICATION SM-6 2026-04-21 Acceptable 2026-05-07